CN101385805B - Traditional Chinese medicine composition containing cicada-shell for treating dermatomyositis and preparation thereof - Google Patents
Traditional Chinese medicine composition containing cicada-shell for treating dermatomyositis and preparation thereof Download PDFInfo
- Publication number
- CN101385805B CN101385805B CN2007101454139A CN200710145413A CN101385805B CN 101385805 B CN101385805 B CN 101385805B CN 2007101454139 A CN2007101454139 A CN 2007101454139A CN 200710145413 A CN200710145413 A CN 200710145413A CN 101385805 B CN101385805 B CN 101385805B
- Authority
- CN
- China
- Prior art keywords
- dermatomyositis
- chinese medicine
- medicine composition
- radix
- angelicae sinensis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention provides a traditional Chinese medicine composition containing cicada shell for treating dermatomyositis and a preparation thereof. The dermatomyositis is classified as 'flaccidity syndrome' by the theory of collateral diseases of the Chinese traditional medicine, and the pathogenesis of the dermatomyositis is mainly the deficiency of the spleen and the kidney, no source for the production and transformation of qi and blood, inability of the weakened body resistance to conquer pathogen, and obstruction of the collaterals of muscles and skin by wind cold dampness, thus affecting the liver, the kidney and the spleen and causing the yin collaterals stasis of internal organs, qi-blood disharmony, and malnutrition of the limbs, skin, tendons and channels. Aiming at treating syndromes of obstruction of channels and collaterals and collateral deficiency caused by pathogen of the dermatomyositis, the traditional Chinese medicine composition determines the treatment based on differentiation of symptoms and signs by the theory of the collateral deficiency of Chinese traditional medicine, and is made from dried rehmannia root, turtle shell, white mustard seed, angelica root, astragalus root, scorpion, spatholobus stem and cicada shell to regulate the nutrient and tonify deficiency, and eliminate the pathogenic factors and activate the channels. Clinical studies prove that the traditional Chinese medicine composition can treat the dermatomyositis effectively.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and preparation thereof that contains the treatment dermatomyositis of Periostracum Cicadae, belong to the Chinese herbal and crude drugs preparations technical field.
Background technology
Dermatomyositis (dermatomyositis, DM) be a kind of striped muscle that mainly involves, apyetous inflammatory myopathy based on lymphocytic infiltration, belong to one of autoimmunity connective tissue disease, the primary disease course of disease is long, the disability rate height is difficult to radical cure, and doctor trained in Western medicine is mainly used glucocorticoid and immunosuppressant treatment.The traditional Chinese medical science is classified as primary disease characteristic symptom and the major lesions mechanism that " myopathy " more meets primary disease.
The dermatomyositis pathogenesis is mainly deficiency of spleen and stomach, and no resource of generating and transforming QI and blood weakened body resistancely can not be driven heresy, and wind and cold is damp and hot to accumulate the network that hinders skin, and then influences the Liver and kidney spleen, causes the internal organs yin collaterals stasis of blood and stagnates, and is qi-blood disharmony, and limbs skin muscle arteries and veins loses supports.The primary disease exopathogen is based on wet, and dampneee being viscous and lingering easily checks mechanism of qi, the humidity hysteresis stagnation of QI, muscle skin meridians impatency is obstructed, its form of expression can have difference, the wet or heat of holding concurrently, or the damp and hot poison that accumulates, or cold-damp go in heat-transformation; Interior-deficiency head blames in the spleen kidney, sees with the deficiency of YIN more, or is the natural endowment deficiency, and cloudy liquid is plain to be lost, or the labor desire is excessively, the smart damage of cloudy consumption, or diseases caused by exogenous pathogenic factor are damp and hot, consumption impairment of QI the moon.The course of disease with the passing of time, deficiency of YIN affecting YANG can be seen syndrome of yang deficiency of spleen and kidney again and wait; No matter invade in the exopathogen, it is puckery still to seek the deficiency of YIN, and no matter sick pathogenic heat noxious dampness is just violated network, still pathogen usually intruding into collateral in protracted disease, and venation is a basic pathology mechanism of dermatomyositis for disease, also is to cause primary disease to show effect repeatedly, delays the principal element that difficulty heals.The clinical manifestation of dermatomyositis: muscle weakness, involve extremity more, can involve cervical region and oblongata myasthenia, even muscle weakness can appear breathing in severe patient; Can accompany skin turgor, or erythema or erythema; Part patient's myalgia.The limb muscle atrophy can appear in late period, and tendon reflex disappears, and severe patient can cause pulmonary fibrosis or paralysis of respiratory muscle death.
The evil channels that stagnates, the not flourish type dermatomyositis of network void, clinical manifestation is: myalgia is as thorn, and attach most importance to night, and the speckle color is dark and gloomy, or leave over pigmentation spots, and squamous and dry skin, arthrogryposis is stiff, acrocyanasis, amyotrophy, that touches has a pliable and tough person, or numb limbs and tense tendons, and tongue is dark or see the petechia ecchymosis, and deep-thready pulse is puckery.Former because: the evil channels that stagnates, venation is retarded by silt, QI and blood is not smooth, impatency skin joint, so the speckle color is dark and gloomy, or leaves over pigmentation spots, arthrogryposis is stiff; Stagnation of blood stasis, so see myalgia as thorn, attach most importance to night, squamous and dry skin; Exopathogen is just being checked wound for a long time, and deficiency of qi and blood, muscle lose supports, so see amyotrophy; Network void is not flourish, passages through which vital energy circulates is not smooth, visible numb limbs and tense tendons, acrocyanasis; Tongue is dark or see the petechia ecchymosis, and deep-thready pulse is puckery to be the evil channels that stagnates, and what network void was not flourish resembles.
Modern medicine is used glucocorticoid, immunoglobulin, immunosuppressant and multivitamin treatment more at present, and wherein glucocorticoid is most widely used general, and is cheap.But the glucocorticoid effect lacks specificity, and life-time service produces various untoward reaction to human body; Immunoglobulin, immunosuppressant then cost an arm and a leg, and are not suitable for life-time service.Tradition Chinese medicine dermatomyositis is also had nothing in common with each other, and the rule of treatment differs.
Summary of the invention
The invention provides a kind of Chinese medicine composition and preparation thereof that contains the treatment dermatomyositis of Periostracum Cicadae.The common pathogenesis of venation pathological changes of dermatomyositis is that the QI and blood or the resistance of seminal fluid numbness of channels is obstructed, so collateral dredging is total Therapeutic Principle.
In the Chinese medicine composition of the present invention, the Radix Rehmanniae is enriched blood profit network, YIN supplementing and fluids increasing with logical arthralgia due to stagnation of blood; The Radix Astragali Radix Angelicae Sinensis activating qi and collateral that is fated, gas fill then blood fortune; Carapax Trionycis, Scorpio, Periostracum Cicadae share searches network by evil; The Semen Sinapis Albae collateral dredging that eliminates the phlegm; Caulis Spatholobi nourishing blood and promoting blood circulation collateral dredging.
The invention provides a kind of Chinese medicine composition that contains the treatment dermatomyositis of Periostracum Cicadae, it is characterized in that being making by the crude drug of following weight portion ratio:
Radix Rehmanniae 6-30 Carapax Trionycis 9-20 Semen Sinapis Albae 9-15 Radix Angelicae Sinensis 9-15
Radix Astragali 15-30 Scorpio 6-9 Caulis Spatholobi 15-30 Periostracum Cicadae 5-10
Preferably, Chinese medicine composition of the present invention is to be made by the crude drug of following weight portion ratio:
Radix Rehmanniae 10-25 Carapax Trionycis 10-17.5 Semen Sinapis Albae 9-15 Radix Angelicae Sinensis 9-15
Radix Astragali 15-25 Scorpio 6-9 Caulis Spatholobi 15-25 Periostracum Cicadae 5-10
More preferably, Chinese medicine composition of the present invention is to be made by the crude drug of following weight portion ratio:
The Radix Rehmanniae 19 Carapax Trionycis 15 Semen Sinapis Albaes 12 Radix Angelicae Sinensis 12
The Radix Astragali 23 Scorpios 7 Caulis Spatholobis 23 Periostracum Cicadaes 7
Or make by the crude drug of following weight portion ratio:
The Radix Rehmanniae 16 Carapax Trionycis 13 Semen Sinapis Albaes 11 Radix Angelicae Sinensis 11
The Radix Astragali 21 Scorpios 7 Caulis Spatholobis 21 Periostracum Cicadaes 7
Or make by the crude drug of following weight portion ratio:
The Radix Rehmanniae 25 Carapax Trionycis 17 Semen Sinapis Albaes 13 Radix Angelicae Sinensis 13
The Radix Astragali 27 Scorpios 8 Caulis Spatholobis 27 Periostracum Cicadaes 9
Or make by the crude drug of following weight portion ratio:
The Radix Rehmanniae 12 Carapax Trionycis 11 Semen Sinapis Albaes 10 Radix Angelicae Sinensis 10
The Radix Astragali 18 Scorpios 6 Caulis Spatholobis 18 Periostracum Cicadaes 6
The preparation formulation of Chinese medicine composition of the present invention is decoction, powder, capsule, tablet, pill or oral liquid.
The dosage form of Chinese medicine composition of the present invention adopts conventional preparation method preparation, and for example, the preparation technology of Fan Biting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition) record makes the acceptable regular dosage form of pharmaceutics.
In the application of the present invention, described Chinese medicine composition is a kind of in decoction, powder, capsule, tablet, pill, the oral liquid formulations, for above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods of acetic acid chloroethene; Substrate comprises: PEG6000, PEG4000, insect wax etc.For making above-mentioned dosage form can realize pharmacy of Chinese materia medica, need when these dosage forms of preparation, to add acceptable other adjuvant of pharmacy (adjuvant of each dosage form record among the Fan Biting " pharmacy of Chinese materia medica ", Shanghai Science Press December in 1997 the 1st edition).
Preferably, the dermatomyositis of traditional Chinese medicine composition for treating of the present invention is the evil channels that stagnates, the not flourish type dermatomyositis of network void.We because of and battalion's tonify deficiency, eliminating evil collateral dredging, so the evil stagnant channels of treatment, the not flourish type dermatomyositis of network void has better effect.
Be confirmation clinical drug curative effect of the present invention, the decoction that use prepares according to embodiment 1 described method (to call in the following text: medicine of the present invention) carried out following clinical observation:
One, clinical diagnosis standard
Standard formulation with reference to propositions in 1975 such as Bohan
1, main standard:
A, typical dermatosis (the purplish red erythra of eyelid), peripheral vessel expansion and finger are stretched side squama erythema or extremity trunk erythema.
B, muscular strength reduce flesh tenderness and scleroma, slow movement and the obvious amyotrophy of extremity peri position.
Inflammatory cell infiltration, edema are seen in c, flesh biopsy, muscle fiber hyalinosis or cavity necrosis, and the muscle fiber thickness differs, interstitial fibrosis, muscle fiber orthogenesis etc.
D, sero-enzyme GOT, GPT, LDH, aldolase etc. surpass normal value 5%.
The existing of e, electromyography showed myositis (use 17-hydroxy-11-dehydrocorticosterone or spasmolytic etc. and then can influence positive findings).
2, minor criteria
A, calcific deposit.
B, dysphagia.
3, diagnositc decision
Possess 3 in 5 of the main standard, or 2 of main standard add 2 of minor criterias, promptly be diagnosed as dermatomyositis (skin symptom is not polymyositis for a long time).
Main standard have only 1 and (or) 2 times, then possess 1 of 2 of main standard or main standard and add 2 of minor criterias and promptly be diagnosed as dermatomyositis.
Special-shaped: with the polymyositis or the dermatomyositis of malignant tumor.
Except: struvite muscle illness or dermatomyositis that reason is clear and definite.
4, traditional Chinese medical science disease diagnostic criteria:
The evil channels that stagnates, the not flourish type of network void
Primary symptom: (1) limb muscle atrophy is unable, and (2) cutaneous pigmentation or erythema (3) acroesthesia is as thorn, acrocyanasis
Inferior disease: (1) dark tongue quality or see the ecchymosis petechia, Tai Bai or Huang, (2) deep-thready pulse is puckery;
(3) the limbs joint contracture is stiff, or numb limbs and tense tendons, or squamous and dry skin (4) macule is dark and gloomy, state of an illness delay.
Two of above primary symptoms or more than add two of time diseases or more than be diagnosed as this type.
Two, data and method
1, physical data:
This research is carried out in Hebei Yi Ling hospital, and all cases meet above-mentioned doctor trained in Western medicine criterion.Age excludes this research greater than 65 years old and the organ injury persons such as severe cardiac, liver, kidney (in the inpatient therapeutic process send out survivor except) of occurring together.Medicine group 121 examples of the present invention are inpatient; Male's 32 examples wherein, women's 89 examples; 14～60 years old age, average 45 years old; The course of disease is smaller or equal to 1 year person's 23 example, 1～3 year person's 46 example, and 4～7 years person's 49 examples, more than or equal to 8 years person's 3 examples, wherein 58 examples met the evil channels that stagnates, and network void is the traditional Chinese medical science disease diagnostic criteria of flourish type not.Matched group 35 examples also are inpatient; Male's 9 examples wherein, women's 26 examples; 15～61 years old age, average 45 years old; The course of disease is smaller or equal to 1 year person's 5 example, 1～3 year person's 19 example, and 4～7 years person's 20 examples, more than or equal to 8 years person's 1 examples, wherein 27 examples met the evil channels that stagnates of the traditional Chinese medical science, and network void is the traditional Chinese medical science disease diagnostic criteria of flourish type not.Treat preceding two groups of patients at aspect difference not statistically significants such as sex, age, the course of disease, degree of being in a bad way.
2, Therapeutic Method:
2.1 medicine group of the present invention: take medicine of the present invention, 600 milliliters of every days, divide twice decoction being taken warmly sooner or later.Glucocorticoid treatment: prednisone 0.8-1.5 mg/day/kilogram.To wherein meet the evil channels that stagnates, the diagnostic criteria of the not flourish traditional Chinese medical science disease of network void be divided into the S1 subgroup, all the other are not inconsistent the combined pathogens channels that stagnates, the traditional Chinese medical science disease diagnostic criteria that network void is not flourish be divided into the S2 subgroup, above-mentioned two hypotypes all adopt identical treatment measure.
2.2 matched group: give glucocorticoid treatment merely, consumption is the same.
3, be 3 months the course of treatment course of treatment.
4, observation index: deflorescence situation, muscular strength, creatine phosphokinase.That observes untoward reaction, relapse rate and hormone simultaneously removes the situation of subtracting smoothly.The muscular strength grade scale is with reference to the grade scale of Britain Medical Res Council.
5, curative effect determinate standard: " the new Chinese medicine clinical research guideline (dermatomyositis) " of Ministry of Public Health promulgation formulated with reference to nineteen ninety-five.
The clinical recovery standard: erythra disappears fully, and the muscle Myodynamia recovery is normal, and it is normal that myocardium enzyme is recovered.
Clinical produce effects standard: the erythra major part disappears, and the muscle muscular strength increases the 2-3 level, and 2 or above measured value descend and surpass 50% in the myocardium enzyme.
Clinical effective standard: erythra partly disappears, and the muscle muscular strength increases the 1-2 level, and myocardium enzyme has 2 or above decline 25-50%.
Clinical invalid standard: erythra does not have minimizing, and muscular strength increases by 1 grade of less than, the myocardium enzyme equal less than 25% that descends.
6, statistical method
Two groups of curative effects relatively adopt rank test, and total effective rate relatively adopts X 2 test.Adopt the SPSS10.0 statistical software, there is statistical significance P＜0.05 for difference; Two subgroup curative effects more also adopt rank test, and there is statistical significance P＜0.05 for difference;
Three, result
1, medication therapy groups of the present invention and matched group curative effect are relatively
Table 1 liang group clinical curative effect analysis (routine number, %)
| Grouping | The example number | Recovery from illness | Produce effects | Effectively | Invalid | Total effective rate (%) |
| Medicine group of the present invention | 121 | ?3(2.5) | 59(48.8) | 37(30.6) | 22(18.2) | 81.8 |
| Matched group | 35 | ?1(2.9) | 7(20.0) | 15(42.9) | 12(34.3) | 65.7 |
Two groups of general curative effects relatively adopt rank test, p=0.004, so medicine group of the present invention and matched group have marked difference on general curative effect, and the matched group that is better than evident in efficacy of medicine of the present invention; Two groups of total effective rates relatively adopt X 2 test, p=0.042, so there were significant differences on total effective rate in matched group for medicine group of the present invention, the effective percentage of medicine of the present invention is significantly higher than matched group.
2, different TCM Syndrome Type curative effects relatively
The different TCM Syndrome Type efficacy analysis of table 2 (routine number, %)
| Grouping | The example number | Recovery from illness | Produce effects | Effectively | Invalid | Effectively total |
| Rate (%) | ||||||
| The S1 group | 58 | 2(3.4) | 33(56.9) | 17(29.3) | 6(10.3) | 89.66 |
| The S2 group | 61 | 1(1.6) | 26(41.3) | 20(31.7) | 16(25.4) | 74.60 |
Two groups of general curative effects relatively adopt rank test, p=0.002, so S1 group has marked difference with the S2 group on general curative effect, medicine of the present invention is for the heresy channels that stagnates, and the not flourish type dermatomyositis of network void evident in efficacy is better than the non-heresy channels that stagnates, the not flourish type dermatomyositis of network void.
Four, conclusion
Chinese medicine composition of the present invention can effectively be treated dermatomyositis, the evil channels that stagnates of treatment, and the not flourish type dermatomyositis of network void has better effect.
The specific embodiment
Example below in conjunction with the preparation of medicine decoction of the present invention, powder, capsule, tablet, pill, oral liquid illustrates the specific embodiment of the present invention.
Embodiment 1:
The Radix Rehmanniae 19 gram Carapax Trionycis 15 gram Semen Sinapis Albaes 12 gram Radix Angelicae Sinensis 12 grams
The Radix Astragali 23 gram Scorpios 7 gram Caulis Spatholobis 23 gram Periostracum Cicadaes 7 grams
Preparation method: Carapax Trionycis adds clear water and is decocted first for 1 liter, boils decoction and adds other crude drug to the half an hour of boiling and continue to decoct, and intense fire decocts to boiling, and continues slow fire boiling half an hour, filters 300 milliliters of extracting juice.Add 500 milliliters in water again, repeat to decoct once, filter, 300 milliliters of extracting juice merge the medicine juice of twice decoction, and mixing amounts to 600 milliliters, promptly get decoction, divides morning and evening twice decoction being taken warmly.
Embodiment 2:
The Radix Rehmanniae 16 gram Carapax Trionycis 13 gram Semen Sinapis Albaes 11 gram Radix Angelicae Sinensis 11 grams
The Radix Astragali 21 gram Scorpios 7 gram Caulis Spatholobis 21 gram Periostracum Cicadaes 7 grams
Preparation method: formulation method is total to the porphyrize foam routinely, makes powder.
Embodiment 3:
The Radix Rehmanniae 25 gram Carapax Trionycis 17 gram Semen Sinapis Albaes 13 gram Radix Angelicae Sinensis 13 grams
The Radix Astragali 27 gram Scorpios 8 gram Caulis Spatholobis 27 gram Periostracum Cicadaes 9 grams
Preparation method: formulation method is made capsule routinely.
Embodiment 4:
The Radix Rehmanniae 12 gram Carapax Trionycis 11 gram Semen Sinapis Albaes 10 gram Radix Angelicae Sinensis 10 grams
The Radix Astragali 18 gram Scorpios 6 gram Caulis Spatholobis 18 gram Periostracum Cicadaes 6 grams
Preparation method: formulation method is made tablet routinely.
Embodiment 5:
The Radix Rehmanniae 21 gram Carapax Trionycis 16 gram Semen Sinapis Albaes 12 gram Radix Angelicae Sinensis 12 grams
The Radix Astragali 24 gram Scorpios 7 gram Caulis Spatholobis 24 gram Periostracum Cicadaes 8 grams
Preparation method: formulation method is made pill routinely.
Embodiment 6:
The Radix Rehmanniae 7 gram Carapax Trionycis 9 gram Semen Sinapis Albaes 9 gram Radix Angelicae Sinensis 9 grams
The Radix Astragali 15 gram Scorpios 6 gram Caulis Spatholobis 15 gram Periostracum Cicadaes 5 grams
Preparation method: formulation method is made oral liquid routinely.
Claims (9)
1. Chinese medicine composition that contains the treatment dermatomyositis of Periostracum Cicadae is characterized in that being being made by the crude drug of following weight portion ratio:
Radix Rehmanniae 6-30 Carapax Trionycis 9-20 Semen Sinapis Albae 9-15 Radix Angelicae Sinensis 9-15
Radix Astragali 15-30 Scorpio 6-9 Caulis Spatholobi 15-30 Periostracum Cicadae 5-10.
2. the Chinese medicine composition of treatment dermatomyositis according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
Radix Rehmanniae 10-25 Carapax Trionycis 10-17.5 Semen Sinapis Albae 9-15 Radix Angelicae Sinensis 9-15
Radix Astragali 15-25 Scorpio 6-9 Caulis Spatholobi 15-25 Periostracum Cicadae 5-10.
3. the Chinese medicine composition of treatment dermatomyositis according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
The Radix Rehmanniae 19 Carapax Trionycis 15 Semen Sinapis Albaes 12 Radix Angelicae Sinensis 12
The Radix Astragali 23 Scorpios 7 Caulis Spatholobis 23 Periostracum Cicadaes 7.
4. the Chinese medicine composition of treatment dermatomyositis according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
The Radix Rehmanniae 16 Carapax Trionycis 13 Semen Sinapis Albaes 11 Radix Angelicae Sinensis 11
The Radix Astragali 21 Scorpios 7 Caulis Spatholobis 21 Periostracum Cicadaes 7.
5. the Chinese medicine composition of treatment dermatomyositis according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
The Radix Rehmanniae 25 Carapax Trionycis 17 Semen Sinapis Albaes 13 Radix Angelicae Sinensis 13
The Radix Astragali 27 Scorpios 8 Caulis Spatholobis 27 Periostracum Cicadaes 9.
6. the Chinese medicine composition of treatment dermatomyositis according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
The Radix Rehmanniae 12 Carapax Trionycis 11 Semen Sinapis Albaes 10 Radix Angelicae Sinensis 10
The Radix Astragali 18 Scorpios 6 Caulis Spatholobis 18 Periostracum Cicadaes 6.
7. according to the arbitrary described Chinese medicine composition of claim 1-6, the preparation formulation that it is characterized in that this Chinese medicine composition is decoction, powder, capsule, tablet, pill or oral liquid.
8. Chinese medicine composition as claimed in claim 7 is characterized in that described decoction, powder, capsule, tablet, pill or oral liquid contain one or more pharmaceutically acceptable excipient.
9. according to the arbitrary described Chinese medicine composition of claim 1-6, it is characterized in that described dermatomyositis is the evil channels that stagnates, the not flourish type dermatomyositis of network void.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101454139A CN101385805B (en) | 2007-09-11 | 2007-09-11 | Traditional Chinese medicine composition containing cicada-shell for treating dermatomyositis and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101454139A CN101385805B (en) | 2007-09-11 | 2007-09-11 | Traditional Chinese medicine composition containing cicada-shell for treating dermatomyositis and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101385805A CN101385805A (en) | 2009-03-18 |
| CN101385805B true CN101385805B (en) | 2011-04-20 |
Family
ID=40475611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101454139A Active CN101385805B (en) | 2007-09-11 | 2007-09-11 | Traditional Chinese medicine composition containing cicada-shell for treating dermatomyositis and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101385805B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104800456A (en) * | 2015-05-02 | 2015-07-29 | 臧孝国 | Traditional Chinese medicine composition for treating polymyositis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1334121A (en) * | 2001-08-31 | 2002-02-06 | 石家庄以岭药业有限公司 | Medicinal composition for restoring cardiac collaterals and its application |
| CN1478518A (en) * | 2003-05-15 | 2004-03-03 | 兰金初 | Medicine for treating lupus erythematosus, dermatomyositis, dermatos clerosis and sicca syndrome |
| CN1650923A (en) * | 2004-02-06 | 2005-08-10 | 王德元 | Medicinal composition for treating theumalism and rheumatism diseases |
-
2007
- 2007-09-11 CN CN2007101454139A patent/CN101385805B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1334121A (en) * | 2001-08-31 | 2002-02-06 | 石家庄以岭药业有限公司 | Medicinal composition for restoring cardiac collaterals and its application |
| CN1478518A (en) * | 2003-05-15 | 2004-03-03 | 兰金初 | Medicine for treating lupus erythematosus, dermatomyositis, dermatos clerosis and sicca syndrome |
| CN1650923A (en) * | 2004-02-06 | 2005-08-10 | 王德元 | Medicinal composition for treating theumalism and rheumatism diseases |
Non-Patent Citations (2)
| Title |
|---|
| 郭刚等.硬皮病从络病论治.《新中医》.2007,第39卷(第3期), * |
| 陆春玲等.从湿论治多发性肌炎.《光明中医》.2002,第17卷(第98期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101385805A (en) | 2009-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102151325A (en) | Traditional Chinese medicine for treating breast diseases | |
| CN101700358B (en) | Medicine for treating acute and chronic nonspecific ulcerative colitis and preparation method thereof | |
| CN102188685B (en) | Externally-applied traditional Chinese medicine powder for treating diarrhea type irritable bowel syndrome and preparation method thereof | |
| CN102058784A (en) | Medicinal composition for treating pulmonary heart disease and application thereof | |
| CN102085315B (en) | Traditional Chinese medicine composition for treating acute and chronic osteomyelitis | |
| CN101254286B (en) | Chinese medicinal composition for curing wind dampness and rheumatoid | |
| CN102512552B (en) | Traditional Chinese medicine composition for treating exogenous fever | |
| CN103041145B (en) | Traditional Chinese medicine composition for treating exogenous fever | |
| CN101385805B (en) | Traditional Chinese medicine composition containing cicada-shell for treating dermatomyositis and preparation thereof | |
| CN104689132A (en) | Traditional Chinese medicine composition for treating psoriasis | |
| CN104547736A (en) | Medicine for treating goiter | |
| CN101385810B (en) | Traditional Chinese medicine composition containing chinemys reevesii for treating dermatomyositis and preparation thereof | |
| CN103908600A (en) | Externally-applied medicine for treating rheumatoid arthritis damp-heat blockage symptom as well as preparation method and administration method thereof | |
| CN101385812B (en) | Traditional Chinese medicine composition containing epimeddium for treating dermatomyositis and preparation thereof | |
| CN101385836B (en) | Traditional Chinese medicine composition containing poria cocos for treating dermatomyositis and preparation thereof | |
| CN101385820B (en) | Traditional Chinese medicine composition containing ephedra for treating dermatomyositis and preparation thereof | |
| CN103212041B (en) | Chinese medicinal composition treating coronary heart disease | |
| CN101502583A (en) | Chinese medicament preparation for treating cholecystitis and gall-stone as well as preparation method thereof | |
| CN115054644B (en) | Traditional Chinese medicine composition for treating diabetic foot and preparation method thereof | |
| CN102526612B (en) | Traditional Chinese medicine composite for curing angina pectoris | |
| CN105770520A (en) | Medicine preparation used for treating coronary heart disease and application thereof | |
| CN105381260A (en) | Traditional Chinese medicine for treating acquired immune deficiency syndrome and preparation method thereof | |
| CN105726849B (en) | It is a kind of for treating the Chinese medicine of diabetes Depression | |
| CN105031023A (en) | Traditional Chinese medicine composition for treating liver cirrhosis portal hypertension | |
| CN104688916A (en) | TCM (Traditional Chinese Medicine) composition for treating psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |